# Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

> **NCT06652633** · PHASE3 · RECRUITING · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 546 (estimated)

## Conditions studied

- Hematological Malignancies

## Interventions

- **GENETIC:** GLPG CAR T-cell therapy

## Key facts

- **NCT ID:** NCT06652633
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-09
- **Primary completion:** 2039-07
- **Final completion:** 2039-07
- **Target enrollment:** 546 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06652633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06652633, "Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06652633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*